Abstract
Axial spondyloarthritis (SpA) is a chronic inflammatory condition causing significant pain and disability. With nearly 50% of patients developing resistance to standard biological therapies, there is a critical need for alternative treatments. This protocol describes the ESNV-SPA study, a double-blind, randomized cross-over clinical trial evaluating non-invasive vagus nerve stimulation (nVNS). By targeting the cholinergic anti-inflammatory reflex, nVNS aims to reduce pro-inflammatory cytokines. The study will involve 120 drug-resistant SpA patients, comparing 12 weeks of active taVNS against dummy stimulation, with a primary endpoint of ASAS20 response.
Introduction: Addressing Drug Resistance in Axial SpA
Axial spondyloarthritis (SpA) primarily affects the spine and sacroiliac joints. While biological therapies (biologics) targeting TNFα and IL-17 have significantly improved outcomes, a substantial portion of the patient population remains underserved due to primary non-response, secondary loss of efficacy, or adverse effects.
The ESNV-SPA study explores bioelectronic medicine as a solution. The central hypothesis rests on the "cholinergic anti-inflammatory pathway" (CAP). In this regulatory circuit, the vagus nerve communicates with the immune system to inhibit the production of pro-inflammatory cytokines like TNFα, IL-1β, and IL-6. By stimulating the vagus nerve non-invasively, researchers hope to "hack" this natural reflex to manage systemic inflammation without the risks associated with long-term pharmacological immunosuppression.
Methods and Study Design
The ESNV-SPA trial is designed as a multicenter, double-blind, randomized 2x2 cross-over study.
The Intervention
The study utilizes a transcutaneous auricular vagus nerve stimulator (taVNS), specifically the Tens Eco Plus.
- Active Stimulation: Applied to the cymba conchae of the left ear, a region densely innervated by the auricular branch of the vagus nerve.
- Dummy Stimulation: Applied to the left ear lobule, which lacks significant vagal innervation and serves as an anatomical control.
- Dosing: Patients receive one hour of stimulation once per week at an intensity of 2–5 mA.
Cross-Over Protocol
To maximize statistical power and allow each patient to serve as their own control, the study employs a cross-over design. Patients are randomized into two sequences:
- Group A: 12 weeks of active VNS, followed by a 4-week washout period, then 12 weeks of dummy stimulation.
- Group B: 12 weeks of dummy stimulation, followed by a 4-week washout period, then 12 weeks of active VNS.
Data Collection and Clinical Endpoints
The study aims to recruit 120 adult patients who have failed at least two biological therapies. Data collection is rigorous, spanning clinical, biological, and quality-of-life metrics across multiple visits.
The primary endpoint is the ASAS20 response at 12 weeks. This composite measure requires at least a 20% improvement (and an absolute improvement of at least 10 units on a 0–100 scale) in three of the following four domains: patient global assessment, total back pain, function (BASFI), and inflammation (BASDAI morning stiffness). Secondary endpoints include changes in C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and specific cytokine levels (IL-6, TNFα).
Discussion and Future Outlook
The ESNV-SPA study represents a significant step in moving VNS from an invasive surgical procedure to a portable, non-invasive therapy. By targeting the cymba conchae, the protocol leverages precise neuroanatomy to trigger systemic anti-inflammatory effects.
However, the protocol faces challenges, such as potential blinding issues if patients perceive different sensations between the earlobe and the cymba conchae. Additionally, the once-weekly stimulation frequency is relatively conservative. If successful, this trial will provide a foundation for optimizing nVNS dosing and potentially integrating bioelectronic medicine into the standard care for refractory inflammatory diseases.
Trial Registration: ClinicalTrials.gov (NCT04286373).
Summary updated